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ABSTRACT

The purpose of the studies included in this thesis is to develop an effective an
efficient method to study the proteome using separation and detection of peptides,
when only a limited amount of sample, 10 micrograms of total protein or less, is
available. The analysis will be applied to multiple myeloma cancer cells using ultra
high performance liquid chromatography-mass spectrometry for expression proteomics
to illustrate utility. To detect low abundance peptides in a complex proteome, we
use different strategies, including basic pH reversed phase liquid chromatography
(bRPLC), mass-to-charge fractionation in the mass spectrometer, and various liquid
chromatography gradients to increase peptide separation to improve opportunities for
detection and quantification. The different methods are optimized and compared by
the number of peptides detected. Step-wise elution of bRP spin columns proved to
yield more than 36,000 peptides using only 10 μg of protein. Mass-to-charge (m/z)
fractionation was tested in mass analyzer Q-Exactive Plus (Thermo Scientific). Liquid
chromatography-tandem mass spectrometry (LC-MS/MS) of unfractionated sample was
analyzed 4 times at different mass ranges, each mass range width of 150 m/z, resulting
from 4 spectra combined, 31,732 peptides representing 3,967 proteins. Showing
vi

comparable results to those form high pH reversed phase fractionation spin columns 5
fractions. Establishing a benchmark where the LC-MS/MS analysis of 600 μg of 10plex
TMT-labeled peptides fractionated with bRPLC into 24 fractions yielded over
74,000 peptides from 7,700 proteins, we compared those results with analysis of 10 μg of
total TMT-labeled peptides fractionated by bRP spin columns into 5 fractions, which
produced 14,019 peptides from 3,538 proteins. These experiments were used to
relatively quantify protein expression in naïve and drug resistant multiple myeloma
cells lines as an example application in cancer research.
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Chapter 1
INTRODUCTION

Proteomics
The field of Proteomics studies the proteins from the cells (the proteome), to
identify and quantify these components expressed in the cell or tissue, with the purpose
to investigate their functions and interactions within the cell or between surrounding
cells. In addition, Proteomics also evaluates changes in the number of copies of proteins
and modifications in the proteins after translation, known as post-translational
modifications (PTM), in response to stimuli (e.g. cancer treatments). Proteomics links
Liquid Chromatography (LC) and Mass Spectrometry (MS), two powerful analytical
chemistry tools, to work in combination to analyze complex samples, like the proteome
of cancer cells.

The Human Proteome is Complex Mixture
One of the hardest challenges in Proteomics is resolving the complexity of the
proteome, particularly with limited sample amounts, as the cases when samples come
from patients or clinical studies. Understanding the chemistry of peptides, we can make
1

an optimal use of these analytical tools, liquid chromatography instruments and mass
spectrometers. These instruments have been applied in the study of different cancer
proteomes. Mertins, et al. with an integrated study describe a deep analysis of
phosphoproteomics (study of phosphorylated proteins) to identify therapeutic targets
in breast cancer.1 Tsai, et al. evaluated changes in protein level in serum from patients
with hepatocellular carcinoma (cancer in the liver) to discover candidates for future
biomarkers2. Sacco, et al. profiled changes in the proteome to demonstrate the
mechanism of anticancer activity of metformin in breast cancer3. Membrane proteins are
usually in low abundance, a study of 11 drug resistant and sensitive lung cancer cells
with different EGFR mutation statues, was able to identify several up-regulated
membrane proteins that showed to be related in lung cancer progression4. Another area
of study involves assessment of enzymatic activity using chemical probes that
covalently modify active sites of enzymes, like tyrosine kinases. Ctortecka, et al. show
how a drug FDA-approved for acute myeloid leukemia, the multi-kinase inhibitor,
Midostaurin, can act on targets in lung cancer cells; the analysis of the
phosphoproteome explains the mode of action of the kinase inhibitor.5 The common
element in these research projects is the use of multidimensional separation prior to LCMS based proteomics as essential tools to help to elucidate molecular pathways,
mechanisms of action, and cancer biomarkers, through the identification and
quantification of complex mixtures of thousands of proteins in cancer samples.
2

Dynamic Range
The complexity mentioned above comes from the dynamic range (difference
between the lowest number and the highest number of copies) as well as the number of
different proteins. In other words, the complexity comes from thousands of proteins
that are not equally distributed in the mixture.6 The proteome dynamic range varies
from sample to sample, from normal cell to cancer cell and between model systems and
patient specimens.
The quest for the detection of proteins at low abundance of these complex
samples is one of the great challenges in Proteomics. It is of great interest in cancer
biology because lower abundance proteins control many important aspects of cell
functions, where critical changes often occur for disease progression or development of
drug resistance. Even when significant changes are occurring in the lower abundance
proteins, this difference can be still overwhelmed by the detection of copies of high
abundance proteins. Because of this limitation in dynamic range, we have interest in
finding analytical methods together with developing additional instruments methods,
to sort and distribute all these molecules into less complex samples, something like
breaking up a proteome into smaller groups and compartmentalizing them into
fractions7 prior to mass spectrometry analysis.

3

Mass spectrometers have become so powerful, due to enormous improvement in
mass accuracy and high resolution8–11, but it is still a challenge to increase sensitivity, as
an example, the QExactive HF (Thermo Scientific)11 can sequence from 90 million down
to 115 copies of a protein per cell in a liquid chromatography-tandem mass
spectrometry experiment (LC-MS/MS) giving this instrument a dynamic range of 5
orders of magnitude10, showing its status as one of top of the line MS instruments.
However, that performance is not able to cover the dynamic range of samples like
serum (10 to 12 orders of magnitude) or the cellular proteome (~7 orders of magnitude)
in a single experiment12–21.
On a logarithmic scale, the copy number of proteins results in a bell shape
curve14, showing a distribution equally divided of the proteome abundance13, see
Figure 1, if the levels of detection only covers to five orders of magnitude, then proteins
with less than 100 copies will not be detected in a sample size of medium-low
micrograms. Increasing sample size would increase the detection of lower abundance
proteins, protein amounts above 100 µg 14 are estimated to be necessary for detecting
such low number of copies, usually not possible with clinical samples. For example,
biopsies typically yield 10-50 µg. In HeLa cells the 600 most abundant proteins
constitute 75% of the proteome22, and human biofluids can be abundant in volume, but
the 50 most abundant proteins account for over 90%15 of total proteins.
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Figure 1. Distribution of Proteome abundance. Protein copies per cell shows a bell
shape distribution in a 7 orders of magnitude expand. Darker blue triangle is what most
Proteins shotgun proteomics detects. At the top of the curve about 5,000 proteins would
be detected with 10^4 number of cells. Darker blue zone together with the blue triangle
is where MS instrument detection range is, detecting up to 7,000 proteins. If MS can
analyze proteins in purple zone it would be in the range of 9000 proteins detected.
Proteins with fewer than 200 copies per cell (light faded blue and purple zone) we
would need larger amount of protein or application of other analytical methods such as
LC fractionation.

There is a relationship between number of copies of proteins per cell and the number of
cells counts necessary to detect lower abundance proteins which can go from one copy
per cell to ten million copies per cell,14 because a specific number of copies of each
peptide is required for mass spectrometry detection, which is typically higher in a
complex. However, the amounts of cell and tissue samples in biological and clinical
research are often very limited. Clinical tissue samples like lung cancer samples in a
tissue microarray can come in hundreds of samples in a small histological slide, about
5

0.3 mm2 sample size, or the case of laser capture micro dissected samples contain 5,000
cells or less as starting material, which converts to 1 to 5 µg of total cellular protein.23–26
Detection of low abundance proteins in small sample sizes (limited in their
amount of protein) is not possible unless sample can be processed in such way that the
peptides are divided and compartmentalized ( via fractionation) into less complex
samples to reduce the dynamic range and consequently increase their chance to be
detected in the mass spectrometer.

Bottom-up Proteomics
The cellular proteome can be investigated either from intact proteins or their
peptides. When proteins are subjected to proteolysis, the analysis of resulting peptides
is known as bottom-up proteomics see Figure 2. Proteins are enzymatically digested,
typically with trypsin, because is reliable, inexpensive, and robust. Then Tryptic
peptides are analyzed in a mass spectrometer through a series of automated
experiments, the first scan is to detect intact ions and is called MS1, followed by a series
of tandem mass spectrometry scans or MS/MS, where selected ions from MS1 scan are
subjected to fragmentation, and the fragment ions from each peptide are recorded into a
tandem mass spectrum called MS/MS or MS2; the number of MS2 depends on the

6

Figure 2. Schematic of Mass Spectrometry based Proteomics. In Bottom–up Proteomics,
samples are lysed to extract the protein, then proteins are digested, typically with
trypsin. Peptides are separated by liquid chromatography, and nebulized into the gas
phase with electrospray ionization and introduced into the mass spectrometer. Peptides
are analyzed by their mass to charge ratio, m/z, and intensity. The highest ion signals are
picked for fragmentation (tandem mass spectrometry), resulting in a fragment ion mass
spectrum. The combined spectra are analyzed with database search software that
assembles the peptides into their corresponding proteins.

instructions from a user pre-determined instrument method. This cycle is repeated over
and over throughout the liquid chromatography gradient. The rationale for this
approach is that we prefer to work with peptides rather than proteins for several
reasons. First, the mass spectrometer has limitations in m/z resolving power and
sensitivity. While, instruments can detect intact proteins, but they are observed in
multiple charges states in congested spectra, reducing the ability to detect them when
compared to a single peak. In addition, we need to consider introducing a complex mix
of analytes into the mass spectrometer instrument; peptide solubility and chemical

7

characteristics are more favorable than for proteins. Peptides also generally perform
better in LC.

Finally, identification is done by fragmenting the molecule and

interpreting the fragment ion data to obtain the amino acid sequence.
Protein fragmentation results in a very complex spectrum due to multiple
charges in fragmentation and large numbers of fragment ions; however, peptide
fragmentation is easier to both predict and read. Bottom-up proteomics does introduce
some challenges, though; while peptides are easier to work than with big protein
molecules, the number of peptides increases over the number of proteins and can
become more difficult to manage.
An example is, if the proteolysis of each protein gives 10 peptides, and 1,000
different proteins are in each sample with 100 copies each, we are digesting 100,000
protein molecules to produce 1 million peptides. Aebersold27 suggests that there can be
up to 20,000,000 copies of proteins per cell, therefore peptide molecules would surpass
that number by a large margin. This example illustrates how proteolytic digestion
increases the number of analytes quickly, and this can also lead to undersampling low
abundance peptides. When great number of analytes are eluted into LC-MS/MS
exceeding the instrument’s dynamic range of detection, low abundance analytes won’t
have a chance of being detected, the complexity of digested proteins overwhelms
detectability of high intensity signal of abundant peptides and an analytical strategy
must be designed to compensate for this complexity, we need to separate (fractionate)
8

them before LC-MS/MS, to overcoming undersampling to increase the opportunity to
those peptides with very low signal.

Separations
Liquid Chromatography
Chromatography is the most common analytical method for separation of
biomolecules. High performance liquid chromatography (HPLC) is the most common
system19,28–30, where a mobile phase is pumped over a stationary phase
(chromatographic column) to separate, enrich, or purify proteins and peptides. This
separation is based on different chemical properties such as hydrophobicity, charge,
and size. Different types of chromatography techniques have been used in proteomics
among these are reversed phase, ion-exchange, size exclusion, and affinity
chromatography. Figure 3 shows five different types of stationary phase most
commonly used for proteomics applications. These are reversed phase (RP) with acidic
pH, or basic pH reversed phase (b-RP) chromatography which uses pH 10, both
separations base on peptide hydrophobicity, more hydrophobic will elute last. Another
type of separation is hydrophilic interactions liquid chromatography (HILIC) as the
name suggests is based in hydrophilicity, and also polar peptides. Last in Figure 3 is
shown, ion exchange chromatography (IEC), which can be strong cation exchange
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(SCX) or strong anion exchange (SAX) depending on the charge of the analyte, positive
charged peptides or negatively charged.

Figure 3. The most common stationary phase interactions in Liquid Chromatography for
peptide separation used as first dimension in Proteomics. Reversed Phase (RP), Basic
Reversed Phase (b-RP), Hydrophilic Interactions Liquid Chromatography (HILIC), Ion
Exchange Chromatography (IEC) that can be strong cation exchange (SCX), and, Strong
Anion Exchange (SAX).

These strategies can be used individually or combined in multidimensional
fractionation strategies in order to maximize the ability of the mass spectrometer to
detect the most peptides, and thereby the most proteins. In 1999 Link et al. 31 presented
a multi-dimensional separation using strong cation exchange and reversed phase resins
packed into a capillary to infuse directly into a mass spectrometer identifying over 100
proteins in a single run31. A year later using a similar strategy, Washburn, et al.32
identified 1,484 proteins from S. cerevisiae sample, and described the approach as
Multidimensional Protein Identification technology (MudPIT). Later in 2011, was 3,000
yeast proteins in 8 hours 33. But mass spectrometers instruments have advanced, in
10

2013, Zubarev14 suggested as a common expectation that the mass spectrometer
approximately identifies 1,000 proteins/hour of instrument analysis LC gradient and
about only 20 proteins per extra hour after 5 hours, in other words the dynamic range
of the sample will reach a plateau after 5,000 proteins.14 Soon after, just a year later,
Kitata, et al. in 2015, identifies 7,700 proteins in 12 hours.34 but, this year, Meier, et al.
reported 10,000 proteins identified in 100 minutes35, with their branded “spider
fractionator” and mass spectrometer modified instrument method showing we can
keep pushing the boundaries and go deeper into the proteome. And yet, the dynamic
range still surpasses that of mass spectrometer, hence, the need of modes of
compartmentalizing the complex proteome samples.
In addition, these highly specific methods are not yet publicly available and may not be
cost effective, so we need to keep working on strategies that can be applied in the
everyday scenarios in our research.
These research efforts digging deeper into the proteome have pre-fractionation in
common. Pre-fractionation is improving the number of protein identifications in less
time, using different chromatographic separations analytical techniques often in batch
mode rather than column format.

11

Ion Exchange Chromatography
There are 2 main forms of ion exchange chromatography, cation exchange and
anion exchange. The more common use in Proteomics is cation exchange, because
enzymatic digestion using trypsin produces basic peptides. Due to the prevalence of
lysine or arginine in the proteome, tryptic peptides are limited in size mostly between
1,000 Da and 2,500 Da and they are frequently observed in mass spectrometry as doubly
charged ion signals due to Lysine or Arginine at the C-terminal and the charge from the
amine group in the N-terminal of the peptide.
Ion exchange chromatography has been a good choice for fractionation43–46 for
proteome analysis, since the 1960’s when it was introduced.28 Well established
protocols47 have been widely available. Peptides elute depending on their acid/base
characteristics. For strong cation exchange (SCX), the more positive charges a peptide
has in solution, then the strongest the bond to the stationary phase. It will therefore
elute the later in the salt or pH gradient. For strong anion exchange (SAX), the more
negative charges associated with a peptide in solution will cause it to elute later in that
gradient. The mobile phase contains an ionic buffer that will interact with the ions and
the negatively (SCX) or positively (SAX) charged stationary phase, disrupting the
binding between the peptide and the column (see Figure 2).
However ion exchange chromatography has two incompatibilities with mass
spectrometry. First, elution solutions have salt, which is not compatible with LC12

MS/MS, so a clean-up step needs be to added. The other is poor resolution. This
eventually translates in poor fractionation and lost signal for low abundance analytes
due to the inability to optimally separate the peptides.

Hydrophilic Interaction Liquid Chromatography
Hydrophilic interaction liquid chromatography (HILIC)48, this method is very
similar to normal phase separation. The more hydrophilic the peptide is, then the longer
it will be retained in the column. This stationary phase retains polar-ionic peptides,
which may not be retained by reversed phase chromatography49. This choice of
separation is gaining popularity as a complement to RPLC.49–53 It has been compared to
other chromatographic separations, and having better orthogonality than high pH
reversed phase29,54 reporting 69% orthogonality with HILIC versus 53% with high pH
RPLC. Bensaddek, et al. 50, compares HILIC with strong anion exchange using
hydrophilic columns55 and results here were very comparable. A recent study analyzed
prostate cancer patients samples using HILIC as choice of fractionation to quantify 729
N-glycopeptides spanning 1,310 unique N-glycosylation sites56. Advances in this
analysis are possible with improvements in column technology as well as HPLC
instruments.

13

Reversed Phased Chromatography
Reversed phase liquid chromatography (RPLC) is the best suited for analysis of
peptides, particularly the most compatible with mass spectrometers due to the simple
solvent systems containing water, organic modifiers, and acid additives. This method
has been proven in shotgun proteomics, where complex mixtures of peptides are loaded
in a column is packed with RP stationary phase, like C-18, 57 and they are eluted with
through a gradient run from aqueous to organic solvent in a liquid chromatography
instrument interfaced directly with a mass spectrometer (see Figure 2).

Basic pH Reversed Phase Liquid Chromatography
The capacity to resolve 2 analytes with similar chemistry in certain conditions,
where they elute very close to each other, and to be able to separate them is not always
achievable in typical reversed phase conditions, which use a specific organic solvent
and acidic pH (~ pH 3). If we change those conditions, different pH for example,
instead of acidic pH they run through basic pH, then differences in their acid-base
chemistry can make them elute well apart.
In recent years, many proteomics investigators prefer basic pH reversed phase
liquid chromatography (bRPLC), also known as high pH reversed phase
chromatography, for peptide fractionation,16,35,37,39,42,58–65 over SCX because this
approach is more compatible with LC-MS/MS, unlike SCX needs a desalting step
14

previous to MS. Another aspect is bRPLC has better resolution than SCX. Orthogonality
between SCX-RP and bRP-RP has been tested and resulted peptide identification is
much superior if bRP is used as first dimension demonstrated by Nakamura et al.54.
If bRPLC fractions are concatenated,66 the analysis of each new fraction will
distribute low abundance analytes across the whole gradient, making this a good choice
for first dimension sample separation. In either online or offline fractionation,67 this
technique is more popular, since it has higher resolving power than the SCX68 as well as
superior separation compared to off-gel isoelectric focusing.39 The method can be
combined with FASP (filter aided sample preparation) or stage tip peptide extraction,
producing results for LC-MS/MS of 20 concatenated bRPLC fractions identifying 57,979
peptides from 5,494 proteins.37
The off-line high pH reversed-phase fractionation is also used for in-depth
phosphoproteomics using TiO2; 30,000 phosphopeptides can be identified with this
approach, when enrichment is done in each concatenated fraction.59 Stage-tips can also
be used with basic pH RP separation used to analyze lung cancer cells for membrane
protein profiling. Example results are 10 µg and 3,983 membrane proteins were
identified from lung cancer cells.4
Or Spintip-base technology (SISPROT) is basically all happens in a pipette tip: protein
digestion, SAX in a C18 bed, and b-RP, from 6 µg of HEK 293T cell lysate, yielded 4,275
proteins with 1.4 hours of MS time, while 30 µg for 20.4 hour resulted in 8,222 proteins
15

including 3,215 annotated membrane, 2000 HEK293 cell, 1,270 proteins; 100,000 cells, 22
hour of MS time, 7,826 proteins.69 A proprietary nano separations device, called the
spider fractionator, works with minimum sample loss. From 100 µg of sample, 10,000
proteins can be quantified out of a total of 11,300 proteins identified64.
Several research groups have developed different analytical strategies to achieve
efficient peptide separation for proteome expression profiling and targeted
quantification, Nagaraj, et al. pre-fractionation of peptides by gel filtration, followed by
SAX for mapping human cancer cell line with 72 fractions total LC-MS/MS instrument
time of 288 hours, resulting in 166,420 peptides detected corresponding to 10,255
proteins from HeLa cells.70 As another example, Yin, et al. observed that they could
detect 50,000 peptides from 4,500 proteins without pre-fractionation in an LC-MS/MS
experiment lasting 8 hours.40
A 3D peptide fractionation strategy using an in-line multidimensional liquid
chromatograph (MDLC) is described as basic pH reversed phase -strong cation
exchange-low pH reversed phase (bRP-SCX-RP) was used to identify 97,309 peptides
from 6,345 proteins, from mouse embryo fibroblast cells in 24 hours, 12 fractions. 42.
Another 3D multidimensional scheme is RP (heptafluorobutyric acid)-High pH RPRP(formic acid) with a final number of 126 fractions resulting in 189 hours of LCMS/MS instrument time identifying 251,166 unique peptides from 14,230 proteins63, the
idea behind this strategy is using different ion pairing reagents to enhance peak shape
16

and retention time. Ion-pairing reagents help to increase the affinity of the peptides to
the hydrophobic stationary phase. Different ion-pairing have different hydrophobicity
and can provide more hydrophobic character to the peptides and help to increase
retention time71,72. Here the first dimension has stronger hydrophobic character due to
the HFBA than the formic acid giving the orthogonality to the separation. 73
Orthogonality for SCX as first dimension is proven to be a good complement but
the salt involved requires an extra step for purification or clean up, requires time and
risk of more sample loss. Most of the proteolysis is based on trypsin digestion the size
and nature of these peptides are mostly hydrophobic. Basic reversed phase mobile
phase is compatible with low pH reversed phased, uses a volatile ion pairing reagent
and same organic solutions. Hydrophobicity nature of peptides and mobile phase
compatibility makes a bRP an excellent choice for first dimension separation.

Multi-dimensional Liquid Chromatography
The combination of all these techniques in mass spectrometry based proteomics
is call multidimensional liquid chromatography, the most common is the combination
of 2 methods, two dimensional liquid chromatography (2D-LC).
In bottom-up proteomics the most common 2D-LC , arrangement is an off-line
first dimension separation, namely basic pH reversed phase, strong cation exchange, or
HILIC, and the second dimension is reversed phase chromatography coupled to the
17

mass spectrometer. Multidimensional separation combines orthogonal separations prior
to LC-MS/MS; different column chemistries or changes in the mobile phases can be used
to achieve different peptide separations. For online LC-MS/MS, acidic pH reversed
phase chromatography is primarily used, so the upfront fractionation strategy must be
a different mode of separation. The idea behind it is to consider different types of LC
column chemistry as first dimension separation before reversed phase liquid
chromatography online with the mass spectrometer. In 2005, Gilar et al. compared 2DLC, using as first dimension: SCX (strong cation exchange), SEC (size exclusion
chromatography) and HILIC (hydrophilic interaction chromatography) as well RP
(reversed phase) and plotted with second dimension reversed phase liquid
chromatography, showing the orthogonality of each 2D experiment.29 Other
combinations are also possible: SCX, as well as strong anion exchange (SAX) using stopand-go-extraction tips (Stage Tip)4,19,30,36–38, which are suitable for small amounts.
Another combination for fractionation was off-gel isoelectric focusing, but with less
success than bRPLC.39
Although there have been reports of high numbers of identified proteins with no
fractionation, example, 4 µg of protein from human umbilical vein endothelial cells
(HUVEC) observed over 50,000 peptides from 4,500 proteins in 8 hours on data
dependent acquisition with a MS/MS survey scan for 75 most abundant precursor
selection on quadrupole-time of flight instrument (Triple TOF 5600 from Sciex).40
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Another 1D experiment where 6,000 proteins identified without fractionation from 5 µg
of metastatic melanoma cell line WM-266-4, over a 6 hour run analyzed using the LTQ
Orbitrap Velos Elite (a hybrid linear ion trap- Orbitrap instrument from Thermo).41 Or
in the case of MCF7 breast cancer cells, 20 µg of total protein yielded 15,813
phosphopeptides (enrichment with TiO2) from 7,875 proteins over 270 min in a QExactive (a quadrupole-Orbitrap from Thermo). 3
There are cases using 3D-LC also. Law et al. 42 used as first dimension high pH reversed
phase, followed by strong cation exchange and final reversed phase in a 24 hours
LC/MS analysis using mouse embryo fibroblast cell line.
Building on these existing strategies, our goal is a method that is straightforward,
reproducible, fast and cost effective.

Fractionation
The purpose of separating the peptides in the first dimension is to
compartmentalize the peptides to distribute chemically similar peptides into different
compartments or “fractions”, to later analyze each fraction individually to access more
of the total proteome.
Other benefit of fractionation is based on the peak capacity of analytical columns.
The combination of 2 columns in the orthogonal separation multiplies the peak
capacity, one column capacity times the second column capacity. Column capacity is
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determined by experimental means, evaluating peak shape, saturation, and back
pressure. There has been attempt to increase peak capacity like doubling the size of the
column74, but increased only by 40% and also the backpressure. Reduction of the
amount of peptides allows to the user to input the maximum amount with no saturation
of reversed phase nanoflow columns used online with the mass spectrometer. The first
dimension can handle relatively large amount of sample, up to 100’s of micrograms, but
reversed phase column coupled with mass spectrometer works with no more than 1
microgram. To achieve highly resolved peaks, column manufacturers have reduced
their particle sizes to less than 3 µm, consequently giving a high back pressure, leading
to ultra high performance liquid chromatography (UPLC). The smaller particle size can
give such higher chromatographic resolution and produce narrow peaks in the
chromatogram, which will have higher intensity and improved chance of detection and
quantification in LC-MS/MS. To considerer which fractionation approach30 is the best
choice in first dimension there are components to take in consideration such column
characteristics, nature of mobile phase and peptides properties (charge, hydrophobicity,
size).
Here, we apply different fractionation approaches using a microscale basic pH
reversed phase chromatography. All fractions do not need to be run in LC-MS/MS
individually, but rather can be combined or be concatenated59. Batth et al.59 provided
data from 96 bRPLC fractions concatenated into 14, which resulted in over 30,000
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phosphopeptides. Therefore, is not necessary to analyze every single fraction
separately if the right combination is made, as will be demonstrated in Chapter 3.

Tandem Mass Tags (TMT)
Tandem Mass Tag75 quantification is based on isotopes of isomers, these isomers
have same number of isotopic elements, in this case 15N and 13C, 76 but in different
positions, creating molecules that have the same mass. TMT molecules have 3 parts
Figure 4. One functional group is primary amine reactive; this part attaches to the
amine groups from the peptide N-termini and Lysine residues. The second part is the
reporter ion group, which will give the quantification information. Each of TMT label
will have a different and specific mass for the reporter ion based on the placement of
the isotope tags. Third, the middle section of the molecule is the mass balance group, as
precisely the name says will balance isotopic elements between the reporter group and
the rest of the molecule to have always the same mass. This middle part also acts as a
spacer between the peptide and the reporter ion group and is designed to assure
fragmentation. The principle of isobaric labeling is that the same peptide in all samples
will fragment under same conditions and a reporter ion will be generated for each
sample’s peptide and give the amount of peptide in each sample.
TMT is now used for deep analysis of the proteome, up to 28,186
phosphopeptides have been identified using TMT10plex in breast tumor cell lysates
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using 1.34 mg of total protein per channel77. Bai et al78 from 40 fractions got 30,000
phosphopeptides for 160 hour of MS instrument time78.

Samples
Multiple Myeloma cell pellets from Kenneth Shain Lab. were provided for this
work. A group of 9 cell pellet, 4 cell lines naïve, and 5 cell lines drug resistant. The cell
lines are, ANBL-6 and ANBL-6/V10R (Bortezomib resistant; KAS-6 and KAS-6/V10R
(Bortezomib resistant); RPMI-8226 and 8226/B25 (Bortezomib resistant) and 8226/LR5
(Melphalan resistant); U266 and U266/PSR (Bortezomib resistant).

Reporter
Balance group
group
(Normalizer)

NH2 Reactive
group

Figure 4. Tandem Mass Tags (TMT) Structure.
TMT consists in 3 different parts: amine reactive
group that binds with peptides; the mass
normalizer group or balance the mass between the
reporter group to form the isotopologues for the
different isotopic labels; and reporter group for
quantitation. Square shows fragment after High
Collision Energy Dissociation (HCD).

22

Chapter 2
METHODS

Sample preparation
Cell Lysis

RPMI-8226 (abbreviated as 8226) cell pellets were obtained from Dr. Kenneth
Shain’s lab. Cells were lysed with the following buffer: aqueous 8 M urea (Thermo
Scientific, 29700), 20 mM HEPES pH 8.0 (Sigma, H-4034), 1 mM sodium orthovanadate
(Sigma, S-6508), 2.5 mM sodium pyrophosphate (Sigma, S-6422), 1mM βglycerophosphate (Sigma, G-9891). Samples were sonicated using 3 bursts with cooling
on ice in between. Each pulse lasted for 15 seconds at 20% amplitude (Branson
Sonifier® SFRACTION150 Cell Disruptors). Then the cellular debris was cleared by
centrifugation for 30 minutes at 10,000 x g, and the supernatant was transferred to a
clean tube. Protein concentrations were measured using Coomassie Plus Bradford
assays (Thermo Scientific, 23236), a colorimetric protein assay using Coomassie blue G250 dye, when bounding to proteins turns solution in blue.
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Trypsin Digestion

Proteins from cell lysate are treated with 4.5 mM Dithiothreitol (DTT) (American
Bioanalytical, AB00490) and incubated for 20 minutes at 60°C to reduce disulfide bonds
on cysteines residues. Then, tubes are cooled on ice. Free cysteine sulfhydryl groups are
alkylated with 11mM Iodoacetamide (IAA) (GE Healthcare, RPN6302) and incubated in
the dark at room temperature for 20 minutes to avoid rearrangement of disulfide bonds.
Immediately proteins are 4-fold diluted with 20 mM HEPES (Sigma, H-4034) pH 8. For
example, to 100 µl of cell lysate containing 100-200 µg of total protein, add 300 µl of 20
mM HEPES pH 8.0, to get urea concentration below 2 M to avoid denaturation of
proteases. Then, trypsin is added in a 1:20 enzyme: protein substrate ratio. Incubation is
carried overnight at 37°C. The next day, the same amount of trypsin is added to
continue digestion for 2 more hours. Digestion of proteins is quenched by acidification
with 20% TFA for a final concentration of 1% TFA with incubation on ice for 15
minutes. Digested lysate was cleared by centrifugation for 15 minutes at 18,000 x g at
room temperature. Supernatant containing cellular protein digest is transferred to a
new tube.
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Peptide purification
Sep-Pak® Classic C18 cartridge columns (Waters, WATT051910) are solid phase
extraction columns, which can be connected to a 10 ml syringe or a vacuum manifold.
The cartridge is washed with 5 mL of 100% acetonitrile and then conditioned using
sequential washes with aqueous 0.1% TFA with the following volumes: 1mL, 3 mL, and
6 mL. Peptides are loaded, and the flowthrough is collected and saved until the
experiment is complete. Once the peptides are bound to the column, they are washed
sequentially with 0.1% TFA in 1mL, 5 mL, and 6 mL volumes. Elution is achieved with 2
ml of aqueous 40% ACN/0.1% TFA three times and then 2 ml of aqueous 50%
ACN/0.1% TFA; all elutions are collected into the same tube. Eluted peptides are
aliquoted in different concentrations (100 µg/µl, 10 µg/µl, and 1 µg/µl) for experiments
with differing amounts of starting material.

Basic pH Reverse Phase Spin Column
Standard Method
Basic pH reversed phase chromatography followed experiments as
recommended in fractionation kit (Thermo Scientific, 84868). Briefly, peptides were resuspended in 300 µl of 0.1% TFA (equilibration solution) and loaded onto the spin
column, which was previously washed and conditioned. After loading, the peptides are
washed with 300 µl of water. Elution follows the steps indicated in Figure 5. Eluted
25

peptides were dried in a vacuum centrifuge. Dry peptides were reconstituted in
aqueous 2% acetonitrile/0.1% formic acid for a final peptide concentration of 200 ng/µl .
Re-suspended peptides were analyzed with LC-MS/MS using a hybrid quadrupole
Orbitrap mass spectrometer (QExactive Plus, Thermo Scientific).

A second experiment was performed with the spin columns following the
method described above, using different pH elution solution. Elution solution contains
same percentage of acetonitrile but we don’t use trimethylamine solution instead, we
acidify with 20% TFA to a final concentration of 1%, giving a set of elution solution of
pH 2.

% ACN

1

2

3

4

5

6

7

Fraction
No.

Acetonitrile
(%)

1
2
3
4
5
6
7
8

5.0
7.5
10.0
12.5
15.0
17.5
20.0
50.0

Triethylamine
(0.1%)
(µl)
950
925
900
875
850
825
800
500

8

Figure 5. High pH Reversed phase spin column. After sample was loaded
into spin column, peptides are eluted in 8 step-wise elution, with increasing
acetonitrile (ACN) concentration. Elution solutions have a final pH 10
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Modified Method 1: Concatenation
Following the protocol described above using High pH Reverse Phase spin
columns, a series of different concatenation strategies were performed, as shown in
Figure 6.

a

b

Concatenate into 2

1

1

2

2

1

Fractions 1, 3, 5, 7

2

Fractions 2, 4, 6, 8

3
Concatenate into 3

c
% ACN

1

1

9: pH 2, 15% ACN
10: pH 2, 50% ACN

1

Fractions 1, 4, 7

2

Fractions 2, 5, 8

3

Fractions 3, 6

Concatenate into 4

2

3

2

4

3

5

9

6

4

7

8

10

1

Fractions 1, 5

2

Fractions 2, 6

3
4

Fractions 3, 7
Fractions 4, 8

5 6

Figure 6. Concatenation. Different number of concatenated fractions were
tested, with 2(a), 3(b), 4(c). The (c) panel is showing an extra 2 elution, after all
8 high pH elution follow 2 more at pH 2. Those pH 2 were not concatenated.
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The same 8 step-wise elution, followed by combination of tubes as the table in
Figure 6 shows, for 4 concatenated fractions small modification was done, we added 2
more: aqueous 15% ACN at pH2 then followed by aqueous 50% ACN at pH2. The 6
fractions were then subject to LC-MS/MS.
Modified Method 2: Sequential Elution
A new approach was tested that will evaluate if reducing the number of elutions
results can be comparable. After loading sample into cartridge elution is done into 4
fractions with basic pH and 2 fractions with acid pH at different acetonitrile
concentrations Acetonitrile concentrations are listed in Table 1. Experiment 4 from table
would be used in Chapter 5 for quantification strategies with chemically labeled
peptides. After eluting 4 step-wise fractions at pH 10, a final elution uses 50% ACN at
pH2. This strategy is depicted in Figure 7.

Table 1. Sequential Elution . Experiments with 2 sequential
elutions at different ACN concentration combined high with
low pH elution.
Experiment

High pH

Low pH

1

15.0%ACN

50.0%ACN

2

10.0%ACN

50.0%ACN

3

5.0%ACN
10.0%ACN
17.5%ACN
50.0%ACN

15.0%ACN
50.0%ACN

4

5.0%ACN
10.0%ACN
17.5%ACN
50.0%ACN

50.0%ACN
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pH 10 elution

% ACN
pH 2 elution

1
2

5

3

6

4

Figure 7. Simplified strategy. No concatenation, sequential 4
elutions, plus 2 elution with low pH solutions. Elutions at pH 10
were tube (1) 5% ACN, tube (2) 12.5% ACN, tube (3) 20% ACN,
tube (4) 50% ACN, followed by tube (5) pH 2/15% ACN, tube
(6) pH 2/50% ACN.

Reverse Phase Liquid Chromatography (LC-MS/MS).
Standard Method Optimized for Diverse Uses in the Proteomics and Metabolomics Core:

The liquid chromatography-tandem mass spectrometry method used is termed
data dependent analysis (DDA), where the instrument. The sample was first loaded
onto a pre-column (2 cm length x 100 µm ID packed with C18 reversed-phase resin,
5µm particle size, 100 Å pore size, C18 PepMap100, Thermo Scientific) and washed for 8
minutes with aqueous 2% acetonitrile and 0.1% formic acid, at rate of 6 µl/min. The
trapped peptides were eluted onto the analytical column, (C18, 75 µm ID x 50 cm
length, 2 µm particle size, 100 Å pore size, C18 PepMap100, Thermo Scientific) The 90minute run uses a gradient program as follows: 98% solvent A (aqueous 2% acetonitrile
+ 0.1% formic acid) for 8 minutes, solvent B (aqueous 90% acetonitrile + 0.1% formic
29

acid) from 3% to 30% in 55 minutes, then solvent B from 30% to 38.5% B in 5 minutes,
ramp solvent B from 38.5% to 90% B in 2 min, and held at 90% B for 3minutes, followed
by solvent B from 90% to 2% in 2 minute and re-equilibrate for 15 minutes at 98% A.
The flow rate on the analytical column was 300 nl/min.

Modified LC-MS/MS Method 1: Flat Gradients

The 90-minute run is tuned to each peptide fraction by modifying the gradient
program as follows: 98% solvent A for 8 minutes, solvent B from 3% to X%B (X: 20%
Fraction#1, 25% Fraction#2, 30% Fraction#3, and 35% Fraction#4), for 55 minutes,
then solvent B from X% to 38.5% B in 5 minutes, then solvent B from 38.5% to 90% B
in 2 minutes, and held at 90% for 3 minutes, followed by solvent B from 90% to 2%
in 2 minutes and re-equilibrate for 15 minutes at 98% A.

Modified LC-MS/MS Method 2: Short Gradient
The standard 90 minute experiment was reduced to a 65 minute run. The
gradient was modified as follows: 98% solvent A for 5 minutes, solvent B from 8%
to 25% B for Fraction #1 and #2, from 15% to 30% B for Fraction#3, from 18% to
35% B for fraction#3, over a shortened time of 40 minutes, then solvent B ramped
up to 38.5% B over 5 minutes, then solvent B ramped up from 38.5% to 90% B in 3
30

minutes, and held at 90% B for 3 minutes, followed by solvent B from 90% to 2% in 2
minutes and re-equilibration for 10 minutes at 98% A.

Mass Spectrometry (MS)
MS Standard Method, Data Dependent Acquisition (DDA) top 16, see Table 2.

Table 2. Instrument Method Parameters for
Data Dependent Acquisition (DDA) Mass
Spectrometry.
Full MS
Resolving power (FWHM at
m/z 200)
AGC Target
Max. injection time (ms)
Scan range (m/z)

70,000
3.00E+06
200
440-2,000

MS2 parameters
Resolving power (FWHM at
m/z 200)
AGC Target

17,500
1.00E+05

Max. injection time (ms)

50

Isolation width (m/z)

2

Offset (m/z)

0.5

Collision energy (NCE)

30

Loop count (Top N)

16

Charge exclusion
Peptide match
Dynamic exclusion (s)
Minimum AGC Targeted

1, >8
Preferred
15
1.00E+03
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m/z Fractionation a Modified MS Method
All the same parameters from the standard method were used except for the
Scan Range in MS1, the full range was divided in 4 different ranges: m/z 350-500, m/z
500-650, m/z 650-800, m/z 800-2000. The same sample was injected 4 times, one LCMS/MS per scan range, using 1 µg each injection.

Data Analysis

MaxQuant79 version 1.5.2.8 for all database searches and peptide and protein
analysis. For label free analysis FDR was set to 0.05% and for TMT was set to 0.01%.

All database searches use UniProt Human from entries updated to May 2018. Peptide
searches include Cysteine carbamidomethylation as a fixed modification and
oxidization of Methionine as a variable modification. For Label free we set up match
between runs with a match window of 4 minutes. For TMT 10plex, reporter mass
tolerance is set to 0.003 Da.

For data analysis, we filter using posterior error probability (PEP) cutoff of 0.05,
elimination of contaminants (matches that are not human) and reverse sequence
matches, which are used to determine false discovery rate. Once data is filtered, we take
the values for each sample from the reporter ion intensities. The differential expression
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calculation for TMT is defined as average log2 ratio plus 2 standard deviations for
significant increases and average ratio minus 2 standard deviation for decreases of the
of resistant over naïve value.

TMT 10plex Peptide Labeling
As described in the manufacturer’s protocol, the technique of labeling peptides is
briefly described as follows. Dry peptides are reconstituted in 100 µl (for every 100 µg)
of 100 mM triethyl ammonium bicarbonate for 30 minutes. TMT labeling reagents are
equilibrated to room temperature, and re-dissolved in 41 µl of acetonitrile, incubated
for 5 min, spun down, transferred into the peptide solution, and incubated for 1 hour.
The following steps are an adaptation into our standard procedure not described in
manufacturer’s protocol. A small aliquot (1 µl of labelled peptides) is diluted into 5 µl
of aqueous 2% ACN/0.1% formic acid and analyzed with LC-MS/MS as a label
incorporation test. If over 95% of the identified peptides are TMT labeled, then the
reaction is quenched using 8 µl of 5% hydroxylamine solution for 15 minutes. Peptides
are ready to be pooled into 1 sample, based on mixing equal amounts of total protein.
The combined sample is lyophilized and fractionated.
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Chapter 3
RESULTS FOR COMPARISON OF DIFFERENT FRACTIONATION STRATEGIES
USING DIGESTS OF WHOLE

Cell Lysates
Cell pellets provided by Dr. Kenneth Shain’s Laboratory, from multiple myeloma
cancer cells, 8226, were lysed with urea buffer and sonication. Cell lysate was digested
with trypsin, then tryptic peptides were purified through C-18 cartridges and aliquoted
for further experiments.
The comparison between LC-MS/MS data acquired for fractions created with
basic pH (bRP) at pH 10 and low pH (RP) at pH 2 is shown in Figure 8. How peptides
are “compartmentalized” and distributed throughout the gradient is depicted in bRP
chromatograms Figure 8a. Each peptide fraction elutes along in different zone of the
gradient. Successful concatenation spreads the peptides across the entire
chromatographic range, combining fractions with minimum overlap to obtain
maximum use of the LC-MS/MS gradient. The only exception would be fraction 4 plus
fraction 8 (shown in blue squares), we see more overlapping for this combination.
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35

F6 (17.5% ACN)

F6 (17.5% ACN)

Low pH RPLC/ low pH RP LC-MS/MS
RP-RP

Figure 8. Chromatogram from 8 step wise bRP spin column. The principle of concatenation is shown in (a)
combination of Fractions (F): F1 (5%ACN) plus F5 (15%ACN) grey box; F2+F6 red box; F3+F7 green box; F4+F8 blue
box. Only the last F at 50%ACN shows significant overlapping in the chromatogram, but the first 3 concatenated
covers most of the chromatogram gradient range with minimum overlapping. (b) gradients are compressed, not
spread out through the chromatogram.

F8 (50% ACN)

F5 (15% ACN)

F5 (15% ACN)

F8 (50% ACN)

F4 (12.5% ACN)

F4 (12.5% ACN)

F7 (20% ACN)

F3 (10% ACN)

F3 (10% ACN)

F7 (20% ACN)

F2 (7.5% ACN)

F2 (7.5% ACN)

b
F1 (5% ACN)

High pH RPLC/ low pH RP LC-MS/MS
bRP-RP

F1 (5% ACN)

a

2D Separations: bRP-RP and RP-RP
Eight fractions from the spin column, regardless of pH, do not completely isolate
peptides in single fractions. Figure 9 shows a histogram for bRP in blue , identifying
32,491 peptides with some in a single fraction and some detectable across all 5 fractions.
Note that the last bar in the histograms correspond to peptides that are uniquely
detected in either low pH or high pH fractionation, and not in the other method, those
are the number of peptides that were only found in the other method. These results are
from running a database search together and we were able to identify peptides that the
other method did not elute. From these histograms, low pH seems to have better
separation, but later we demonstrate that most of those peptides observed in only 1
fraction come from at the last elution with 50% acetonitrile elution.
A Venn diagram in Figure 10 shows about 10,100 peptides unique form bRP-RP,
separation is not sharp peak but effective. We can conclude that 2D bRP-RP validates
orthogonality comparing with RP-RP in number of peptides identified. These lower
numbers of peptides in RP is shown in the chromatogram being compressed and not
spread out in the gradient. Since RP-RP works with the same acetonitrile concentration
in both dimensions chemistry of peptides is the same and all from one fraction trying to
elute same time.
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Number of Petides
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Figure 9. Distribution of Peptides in Eluted Fractions from Spin Columns. We found
that peptides can elute in quite number of fractions in bRP. At basic pH peptides seems
to have quite unique hydrophobicity/hydrophilicity properties since they showed to
elute in quite number of fractions. At low pH elution, peptides resolve better than in
high pH. The last bar are peptides only from the opposite approach, this is due to
database searches were done within the same analysis file.
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Proteins

Peptides

Figure 10.Venn Diagram of Peptides Detected with LCMS/MS in Unfractionationed and Fractionated Digests.
Comparison between unfractionated and bRP-RP and RP-RP
showed that 10,100 more peptides were identified with an
orthogonal approach , and , that number of identified
peptides is significantly higher when fractionation is
performed.

Comparing Different Strategies.
To help elucidate the orthogonality of the process and understand the
hydrophobicity process of these 2 approaches, Table 3 shows the percentage of
peptides that low pH also elutes in each of the elution solution at pH 10, at 5% ACN 8%
of the peptides identified at pH 10 (6,351 peptides) were eluted by 5% ACN pH 2.
Conversely at 50% ACN pH 10, more than half of them are also eluted at pH 2. Some
peptides’ hydrophobicity are not affected by the pH of the mobile phase, those will
elute in the same organic concentration no matter the pH of the solution.
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Despite of peptides eluting in more than 2 fractions, or hydrophobic peptides
that pH won’t change their chemistry, the number of peptides with highest intensity
will be better distributed in bRP than RP fractionation, as Table 4 shows.

Table 3. The Percentage of Common Peptides. Overlap found Between low pH from high
pH Fractions. Percentage of the same peptides found in low pH from the from each high pH
fragment.
High pH fractionation
1

2

3

4

5

6

7

8

(5% ACN) (7.5% ACN) (10% ACN) (12.5% ACN) ( 15% ACN) (17.5% ACN) (20% ACN)

(50% ACN)

1
8%

6%

5%

5%

5%

5%

5%

5%

14%

9%

8%

7%

7%

7%

7%

7%

29%

18%

13%

11%

11%

11%

11%

13%

41%

31%

23%

20%

19%

18%

18%

21%

41%

39%

34%

31%

28%

28%

28%

29%

34%

39%

41%

39%

36%

36%

36%

34%

29%

38%

43%

43%

42%

41%

41%

39%

22%

31%

42%

49%

53%

55%

57%

51%

(5% ACN)
2
(7.5% ACN)
3

Low pH fractionation

(10% ACN)
4
(12.5%
ACN)
5
( 15% ACN)
6
(17.5%
ACN)
7
(20% ACN)
8
(50% ACN)
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Table 4. Fraction containing peptide with the highest intensity. Number of peptides in
bRP-RP is evenly compartmentalized, comparing to RP-RP. Number of peptides are
more evenly distributed in bRP, whereas RP tend to elute at higher organic.

When chromatograms in Figure 8 are analyzed, we wondered if changes in the gradient
could make a difference in both peptide identification and MS time optimization. As
Figure 11 shows, our LC method is optimized to maximize peptide detection.
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20000

Peptide Count

19500
19000
18500
18000
17500
17000
Short gradient

Flat gradient

Regular gradient

Figure 11. Modified gradient comparison. LC tested different
gradients for different % organic fractions and compared to our
standard gradient, which turned out to be the optimized method.

2D Separation
bRP-RP and RP-RP
35000
Peptides Count

30000
25000
20000
15000
10000
5000
0
No.Peptides

High pH

Low pH

Un-frac

32491

23954

13442

Experiment

Figure 12. Comparison of Fractionation Strategies. There is significant increase
in identified peptides when orthogonal fractionation is applied.
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As shown in Figure 12, good compartmentalization of peptides does not always
mean more identifications. It also shows that combination of different pH elution can
complement each other to elute higher numbers of different peptides, orthogonality.
The starting point is 32,491 peptides from 8 fractions from bRP-RP doubling that from 3
runs from unfractionated sample. Then observation based on Figure 8, the pattern of
fractionation is clearly lay out and help us to design the strategies for concatenation.
The main idea is utilizing the entire gradient for peptides elution, with minimum
overlapping and reducing MS time by reducing the number of fractions. Following
concatenation strategies described in Modified Method 1, concatenated into 2 gave
22,779 peptides, 3 concatenated 27,109 and 4 concatenated samples 29,710, follow
Figure 13. This experiments resulted in the loss of detection of peptides comparing to 8
fractions by less than 9% for 4 concatenated, loss of 15% for 3 and by 30% less detected
peptides for 2 concatenations, and yet, these concatenated into 2 samples is much
higher, by 39%, than running 3 LC-MS/SM of unfractionated sample, repeating analysis
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Different strategies using bRP spin
column
Unique Peptides Count

40000
35000
30000
25000
20000
15000
10000
5000
0
Unfrac
(3)

High
pH (8)

Conca_ Elute_4
Low Conca_ Conca_ Conca_
Elute_4 4 plus
plus
pH (8)
2
3
4
pH2
pH2

# of Peptides 16388

32491

23954

22779

27109

29710

29977

37164

36336

Figure 13. Study of different strategies with bRP spin column. Comparison between
unfractionated, 8 Fractions with standard protocol at pH 10 elutions as well as 8
elutions at pH 2. Concatenation from 8 eluted fractions into 2, 3 and 4 fractions.
Sequential elution 4 fractions only and last 2 bar graphed are compared concatenated
into 4 plus 2 fractions from low pH elution (37164 peptides), and sequential elution 4
fraction plus 2 elutions with low pH solution (36,336 peptides). Number in parenthesis
indicate number of samples. Error bar in included, it is hard to see since CV% is less
than 1%, the highest is 5% for Concatenation 4.

does not avert undersampling, but analysis of additional fractions improves sampling.
Instead of concatenating into 4 fractions, if we simply elute directly into 4 fractions and
follow Modified Method 2, then this experiment resulted in 29,977 peptides,
practically the same result as was generated from the concatenation strategy. The last 2
bars from Figure 13 are the same sequential elution with 4 fractions with pH 10 elution
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solutions plus additional elutions with solutions at pH 2. Adding 2 fractions of pH 2
increases detected peptides by 15% for concatenated and 13% to the elution 4, this
variability of 2% falls into the 5% of coefficient variation percentage. We have increased
by 3,845 more peptides with less bench work time and most importantly less
instrument time. An overnight LC-MS/MS instrument analysis produces results the
following day (See Table 5).
Based on the results from the histogram Figure 8 together with Table 3, an
analysis of the hydrophobicity based on peptide hydropathy80 together with their
isoelectric point, was plotted using a free tool found in www.gravy-calculator.de and
isoelectric point (pI) from ExPASy (https://www.expasy.org/). The results showed that
peptides are tightly grouped into packets of narrow pI values81. Peptides are small,
compared to proteins, where bigger number of acidic or basic residues can make a
significant change in hydrophobicity and pI, whereas in peptides only few residues, as
low number as 1 residue per peptide to almost the number of amino acids are counted
to influence the hydrophobicity and pI (see Figure 14).
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Table 5. Compilation of b-RP experiments. Comparison of total time of each experiment
number of MS runs and the number of peptides resulted. Here we can see 14 hours of total
time with only 6 samples can get us better results than that of 19 hours.
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Figure 14. Plot of Grand Average of
Hydropathy and pI. Grand Average
Hydropathy (GRAVY) is a calculator of
hydropathy of peptides based on the
sum of amino acid hydropathy divided
by its number of amino acids in the
peptide. Plot of peptide from 2
sequential elution, GRAVY against pI,
common peptides between elution with
pH 10 solution follow by pH 2 and
unique peptide from both elutions.
Lower organic concentration showed
separation at lower pI values, but the
common peptides yet cover most of the
pH range.

pI

Increasing Content via m/z Fractionation
An unfractionated sample was run in mass spectrometer 4 times at different m/z
ranges, giving 4% less peptide-level data when compared to fractionated peptides
analyzed with 5 LC-MS/MS experiments. From Figure 14, the m/z range 350-500 looks
the most crowded in the total ion chromatogram. This range was further divided into
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m/z 350-425 and m/z 425-500 ranges, but it did not improve number of identifications
(data not shown).
The advantage that this method could have is to identify peptide in different
charge states that otherwise wouldn’t be picked up. If a 2+ charge peptide is not chosen
for MS/MS, a less abundant 4+ or 1+ charge could be picked up for fragmentation. In the
most crowded region of m/z 350-650, when divided into 2 experiments increase the
opportunities for difficult to detect peptides to be analyzed. The number of peptides,
31,732, from 3,967 proteins from only 4 runs are already comparable with 5 runs from
bRP fractionation. We observe that at lower m/z ions elute early in the gradient, and
those of a higher masses elute later in the gradient (See Figure 15).
For 4 runs with no offline fractionation, directly unfractionated sample is
compared with 5 fractions from bRP spin column, Figure 16. Results suggest that there
is room for improvement, since protein identification failed for almost 1,000 less
identified proteins almost 20% less, even though peptides are just only 5% less than
those identify by bRP, but the fact that sample get less manipulated chances of loss of
sample gets minimized, as well as does the amount of bench work.
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Figure 15. Chromatogram of m/z Fractionation. LC-MS/MS of same
unfractionated sample 4 times at 4 using different m/z range values., which are
listed in each panel.
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Figure 16. Graph of m/z fractionation in MS. Fractionation
from off-line LC high pH RP, 5 fraction for LC-MS/MS and 4
fractions from MS instrument fractionation.
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Chapter 4
ANALYSIS OF MYELOMA DRUG RESISTANCE

We aim to find a method to maximize the number of identifiable and
quantifiable proteins using microgram amounts of protein digest, and apply this
method to the examination of cancer proteomes to solve basic science and translational
research problems.

Proteomics of Myeloma Drug Resistance
To evaluate the application of the platform described in the previous chapter,
proteins expression of 9 Multiple Myeloma cell lines (Table 10), were quantified using
chemical labeling with TMT10plex reagents (Thermo Fisher Scientific). Relative
quantification using multiplexed isobaric tags is an analytical strategy that has been
developed rather recently and quite quickly since the advancement of mass
spectrometers, the resolving power is also capable to distinguish mass differences of
0.0063 Da82, thanks to the high resolution, and high mass measurement accuracy that
new technology has brought. Highly multiplexed tagging means more samples can be
pulled together into 1 LC-MS/MS experiment in order to simultaneously measure the
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same peptide in all samples at once, making isobaric tagging an ever growing
quantification method65.
Quantification can be achieved in 2 fashions: label free peptides or labelled
peptides. Label free quantification is a simple bottom-up method analyzing the samples
in the MS and comparing intensities or integrated ion signals\. Labeling can be
performed at the protein level or the peptide level. Metabolic labeling can incorporate
labels in the cell as proteins are made; this strategy is called SILAC (Stable Isotope
Labeling with Amino Acids in Cell culture)83. Introduced by Mann’s group in 2002,83 it
can analyze differential proteomics levels, but has 2 important limitations, one only can
be apply to cell cultures, and second, the maximum samples was 3 (using low,
medium, and high isotopic labels). Isobaric labeling at the peptide level Includes
Isobaric Tags for Relative and Absolute Quantification (iTRAQ)84 with 4plex and 8plex
experiments and Tandem Mass Tags (TMT)75 for 6 , 10 or 11 samples for TMT.

TMT 10plex of 9 Multiple Myeloma Cell Lines
Quantification of protein expression between naïve and drug resistant of cell
lines was done using TMT10plex see Table 6.
For this experiment we labeled 100 µg of each melanoma cell line with
TMT10plex reagent. Pool sample consisted in 25 µg of each naïve cell line, 4 naïve and 5
drug resistant cell lines85–87
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Table 6. TMT10plex Labeling of Multiple Myeloma Cell Lines.
The pool is created from equal amounts of the 4 naive amounts
of 25 µg for total of 100 µg in total, quantification of 5 drug
resistant and 4 naive cell lines is performed in this experiment.
Status

TMT10plex
label

naïve

126

Bortezomib resistant

127N

naïve

127C

Bortezomib resistant

128N

naïve

128C

8226/B25

Bortezomib resistant

129N

8226/LR5

Melphalan resistant

129C

naïve

130N

Bortezomib resistant

130C

naïve

131

Cell Line
ANBL-6
ANBL-6 /V10R
KAS-6
KAS-6/ V10R
8226

U266
U266/PSR
Pooled naïve cells

Results
Fractionation for benchmarking experiment with 24 concatenated fractions
proceeded with 600 µg of TMT labeled peptides in bRPLC, collecting 96 fractions and
concatenating to 24 for LC-MS/MS global protein expression profiling of 4 naïve
multiple myeloma cell lines and 5 drug resistant cell lines. In parallel to this
benchmarking experiment to generate a large scale dataset, smaller aliquots (10 µg of
TMT labeled peptides) were loaded into bRP spin column for sequential elution of 5
fractions as described earlier in Table 1. See Figure 17 for schematics of quantification
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Figure 17. Schematic representation of TMT 10plex Experiment. Benchmarking of proteome content was performed using 600
µg of 10 pooled TMT labeled samples for high pH reversed phase liquid chromatography fractionation. Collected samples were
concatenated into 24 for LC-MS/MS. In parallel, 10 µg aliquots of protein digest were loaded in to high pH reversed phase spin
column eluting 4 fractions with pH 10 sequential elution plus 1 elution at pH 2.

strategy. LC-MS/MS of these 5 fractions yielded to a total of 14,019 peptides identifying
3,589 proteins, compared to 74,217 peptides from 7,096 proteins that resulted from 24
Fractions. Figure 18 shows in panel b peptide distribution of Log2 ratio of resistant
LR5 over naïve 8226 cell lines for both benchmark and 5 fractions experiments,
demonstrating quantification is possible even for small scale fractionation.
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Figure 18. Total Peptide and quantification of LR5/8226 ratio. a) Total protein
identification from TMT10plex of 9 multiple myeloma cell lines from a benchmark
experiment consisting in 24Fx/600 µg input in first dimension fractionation, and bRP
spin column 5Fx/10 µg input. B) Protein distribution for Log2 LR5/8226 ratio for both
experiments 5Fx/10µg and 24Fx/600µg.
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Total proteins identified from the benchmarking is 7,145 from 24 fractions that
were concatenated from 96 wells from bRPLC fractionation with 600 µg input, injecting
for LC-MS/MS 1 µg each fraction (total 24 µg). For 5 bRP spin column, input amount
was 10 µg and injection for LC-MS/MS 1.5 µg for total of 7.5 µg shown in Figure 19.
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Figure 19. Total Protein and quantification of LR5/8226 ratio. a) Total protein
identification from TMT10plex of 9 multiple myeloma cell lines from a benchmark
experiment consisting in 24Fx/600 µg input in first dimension fractionation, and bRP
spin column 5Fx/10 µg input. B) Protein distribution for Log2 LR5/8226 ratio for both
experiments 5Fx/10µg and 24Fx/600µg.
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8000

Results show protein distribution is comparable from benchmark and small
scale, log2 ration of LR5/8226 distribution from 600 µg in bRPLC, or from 10 µg input in
spin column is still possible to detect fold change.
Quantifiable proteins from bRP spin columns were almost as many as the
identified over all, 3,538 proteins quantifiable while total was 3,589. The 24 fractions
benchmark experiment identified 7,096 quantifiable proteins out 7,145 proteins as
shown in Figure 20.

226

Increased
Proteins

3312

3784

Decreased
Expression

Figure 20. Quantifiable Proteins. From 24 fractions 7,096
proteins were quantifiable, and 3,538 from 5 fraction
with an input for fractionation of only 10 µg. Increased
expression or decreased expression: is the Log2 ratio of
LR5/8226 average plus 2 SD (standard deviation)
increased expression, or minus 2 SD for decrease
expression for myeloma cell lines.
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We found that differential expression of proteins from bRPLC and bRP spin
column seem to be quite not the same. Proteins that are quantifiable and presented
differential expression either increased or decreased, few concur to both methods.
Significant expression results from 5 fractions, 16 out of 73 proteins agreed with
24 fraction benchmark experiment as having increased expression over 8226 cell line,
the remaining 57 (except for 2) we found them in the set of 24 fractions but not
considered significant. Same situation with the decreased expression proteins, 50% of
them are shared with the other method but the other 50% only spin column method. In
the decreased expression 6 proteins were found in 5 fractions that were not identified
by the 24fraction method.
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Chapter 5
CONCLUSIONS AND FUTURE DIRECTIONS

This thesis has examined different options in response to the need to develop
fractionation methods to maximize detection and quantification of the proteome for
limited sample amounts that are affordable, reliable, and practical. We here are adding
to the workflow a quantification step, when we can identify and quantify over 36,000
peptides from 3,500 proteins, with only 5 LC-MS/MS, and an input of 10 µg of sample,
with a turnaround of 1 day it worth to consider to include it in a core regular
methodologies. An example of typical day would be, is once we have dry peptides, a
day work of fractionation, overnight MS analysis (16 hours from 6 fractions), next day
data analysis, for a core facility turnaround results is important as any aspect of good
service.
Quantification and multidimensional protein identification technology
(MuDPIT) strategy can also be paired in an on-line manner because sample loss from
offline process is inevitable88, to avoid that we are finding new ways to conserve the
sample. Here, we presented m/z fractionation, a practical alternative of sample loss due
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to less manipulation, here it certainly needs more tuning and optimization but the fact
that directly from sample purification into the MS it worth exploring.
No single process or analytical technique is capable of giving us data for all of
the low abundance proteins due to the extensive dynamic range of the proteome.
However, as we continue to improve the analytical strategies and develop new
approaches and new technology, based on knowledge of peptide chemistry and
analysis of large scale data sets. New instruments pushing the limits of resolving power
and improved software that can handle such enormous complex information, making
possible to handle increasingly complex multiplexing projects.
Results showed and interesting fact, that there are peptides that are not eluted
with neither only pH 10 nor only pH 2 elution buffers. There are peptides retained in
the column if only one condition is applied, and with the combination of both pH 10
and pH 2 up to 15% (based on 8 fractions) more peptides are eluted and identified with
less fractions (6 fractions) and less labor.
Our future work is heading in the combination of basic/acidic pH together with
m/z fractionation, a balance between off-line fractionation and MS, between sample
preparation and MS running time. Aspects within MS instrument method that can be
have adjustments for tuning, like isolation window, AGC target, injection time needs to
be analyzed in more detail to avoid undersampling as well as oversampling.
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